Intellectual Property India Publishes Patent Application for 'A Novel Anti-Cd20 Chimeric Antigen Receptor, Its Nucleic Acid Sequence, And Its Preparation' Filed by Indian Institute Of Technology

MUMBAI, India, Feb. 27 -- Intellectual Property India has published a patent application (202521003480 A) filed by Indian Institute Of Technology, Maharashtra, on Jan. 15, 2025, for 'a novel anti-cd20 chimeric antigen receptor, its nucleic acid sequence, and its preparation.'

Inventor(s) include Purwar, Rahul Kailash; and Chowdhury, Ambalika.

The application for the patent was published on Feb. 27, under issue no. 09/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to humanized chimeric antigen receptor (CAR) constructs designed to target CD20-expressing cells. These CAR constructs include a humanized single-chain variable fragment (scFv) derived by grafting complementarity-determining regions (CDRs) from a murine anti-CD20 antibody onto human framework regions, significantly reducing immunogenicity. The CAR constructs feature a human CD8a-derived hinge and transmembrane domain, along with intracellular signalling domains from 4-1BB and CD3?, enhancing immune cell activation and persistence. Nucleic acid sequences encoding these CARs are codon-optimized for expression in human immune cells."

Disclaimer: Curated by HT Syndication.